Benefit business performance is growing rapidly, Hainan pharmaceutical company plans to expand production of no more than 850 million convertible bonds

"
Pharmaceutical Network Enterprise News" recently, located in Hainan, Puli Pharmaceutical announced that it intends to issue no more than 850 million yuan of convertible bonds to non-specific objects for the pulitzer International high-end production line expansion projectpublic information shows that Puli Pharmaceuticals is specialized in drug research and development, production and sales of high-tech enterprises, the company's main products include nonsteroidal anti-inflammatory drugs, anti-allergy, antibioticsIts main product, the ground chlorate, is fixed for the national torch projectIn March 2017, Puli Pharmaceuticals successfully listed on the GEMsince its listing, the company's main business scale continued to expand, the rapid growth of operating performanceIn 2017-2019 and January-March 2020, the Company's operating income was RMB325 million, RMB624 million, RMB950 million and RMB170 million, respectively, while net profit was RMB984.44 million, RMB181 million, RMB 301 million and RMB808.09 million, respectivelyAll of them hit record highs in 2019The company's gross margin for the year was also as high as 85.21 percent, and the net margin was 46.88 percentin addition, in 2017-2019, the company's cash dividend amount was RMB19,538.8 million, RMB38.4671 million and RMB60.4482 million, respectively, and the cumulative cash distribution in the last three years totaled RMB118 million, accounting for 61.17 percent of the annual distribution profitafter years of development, the company has mastered the international quality of recognized production technology capabilities, reserves a number of better market potential injection varieties, has been a number of international drug approvalAs a result, Puli Pharmaceuticals is also actively involved in international competition while meeting domestic demand2019, Pripharmaceutical's overseas revenue achieved 86.3915 million yuan, up 135% YoY, accounting for 9% of total revenue, and the amount of approved products released was significantInjection products, including ebitapeptide injections and injections of liquid hydrochloric acid vancomycin, were approved in the United States, and injectable products such as azithromycin, voltaconazole, and left ethyl lacitan injections were also approved in the United Kingdom, Germany and other countriesRecently, wholly-owned subsidiary Zhejiang Puli drug left oxyfluorosa tablets have also been approved by the Dutch Drug Evaluation Commission in terms of the domestic market environment, the demographic dividend overlay policy dividends, and with the upgrading of consumption, the pharmaceutical industry demand capacity is expected to further increase Under the background of the expanding demand of medicine in our country, Puli Pharmaceutical intends to raise funds to expand production company believes that this fund-raising investment project in line with China's pharmaceutical industry transformation and upgrading and upgrading the requirements of internationalization, through the construction of high-end production lines in line with international quality standards, to improve the company's injection production level, in line with the national industrial strategy announcement shows that the total investment of the project is 1 billion yuan, the proposed to invest 850 million yuan, the project construction period of 5 years, the project construction site is located in Haikou City The construction period is divided into two phases, a total of 10 production lines The first phase of the fund-raising project is 3 years, including injection building, raw material slot, finished product library construction and 2 freeze-dried powder needle production line, 3 injection production lines, 1 "three-in-one supporting powder distribution line" production line The second phase is 2 years, including the completion of 3 freeze-dried powder needle production line, 1 injection line in addition, this fund-raising investment project will introduce some domestic and foreign production equipment and QC testing equipment, the process of sterile production control technology, terminal sterilization injection production control technology, freeze-dried preparation production control technology and integrated intelligent manufacturing platform, applied to the scale of product research and development and production.